Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erica L Mayer

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
JACC. Cardiooncology|August 16, 2021
Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast CancerErica L Mayer
Current Oncology Reports|February 27, 2015
Targeting breast cancer with CDK inhibitorsErica L Mayer
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Early and late long-term effects of adjuvant chemotherapyErica L Mayer
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Inhibition of cyclin-dependent kinases 4 and 6 in breast cancerErica L Mayer
Cancer|February 10, 2023
What's the reality for CDK4/6 inhibitors: Clinical trials or real-world evidence?Dario Trapani, Erica L Mayer
The Lancet. Oncology|October 31, 2024
The state of the science of oral selective oestrogen receptor degradersKristina Fanucci, Erica L Mayer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Long term follow-up of national surgical adjuvant breast and bowel project trial B-31: how well can we predict cardiac toxicity with trastuzumab?Erica L Mayer, Nancy U Lin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2016
Chemotherapy for Triple-Negative Breast Cancer: Is More Better?Erica L Mayer, Harold J Burstein
Breast (Edinburgh, Scotland)|August 18, 2015
Adjuvant endocrine therapy for postmenopausal women: Type and durationErica L Mayer, Harold J Burstein
The Lancet. Oncology|February 19, 2026
Towards response-adapted neoadjuvant breast cancer treatmentGuilherme Nader-Marta, Erica L Mayer
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
JACC. Cardiooncology|August 16, 2021
Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast CancerErica L Mayer
Current Oncology Reports|February 27, 2015
Targeting breast cancer with CDK inhibitorsErica L Mayer
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Early and late long-term effects of adjuvant chemotherapyErica L Mayer
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Inhibition of cyclin-dependent kinases 4 and 6 in breast cancerErica L Mayer
Cancer|February 10, 2023
What's the reality for CDK4/6 inhibitors: Clinical trials or real-world evidence?Dario Trapani, Erica L Mayer
The Lancet. Oncology|October 31, 2024
The state of the science of oral selective oestrogen receptor degradersKristina Fanucci, Erica L Mayer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Long term follow-up of national surgical adjuvant breast and bowel project trial B-31: how well can we predict cardiac toxicity with trastuzumab?Erica L Mayer, Nancy U Lin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2016
Chemotherapy for Triple-Negative Breast Cancer: Is More Better?Erica L Mayer, Harold J Burstein
Breast (Edinburgh, Scotland)|August 18, 2015
Adjuvant endocrine therapy for postmenopausal women: Type and durationErica L Mayer, Harold J Burstein
The Lancet. Oncology|February 19, 2026
Towards response-adapted neoadjuvant breast cancer treatmentGuilherme Nader-Marta, Erica L Mayer
Pageof 12